Enrolling Clinical Studies
URTICARIA CLINICAL TRIAL
This study will evaluate the efficacy of the oral medication remibrutinib compared to dupilumab at early timepoints in adults with Chronic Spontaneous Urticaria inadequately controlled by second generation H1 antihistamines.
Requirements:
-
Men and Women 18 years of age or older at the time of signing the informed consent.
-
Subject with Chronic Spontaneous Urticaria duration for more than 6 month.
-
Subject with inadequately controlled of H1- Antihistamines.
-
Presence of itch and hives for more than 6 weeks prior the screening.
-
No subjects with previous use of remibrutinib or dupilumab.
-
No subjects with significant cardiovascular disease, neurological, pulmonary, renal, hepatic.
-
No subjects with history of hematological disorders (including coagulation).
-
No history of other skin diseases with chronic itching like psoriasis, atopic dermatitis, etc.
-
No pregnant women or without a highly effective method of contraception.
-
Subject must have a valid ID and not be participating in another research study.
Study Duration:
This study contains a total of 8 in-clinic visits over a period of 12 weeks and 2 telephone contacts at Week 16 and Week 24
Compensation:
This study will pay $100 per office visit and $50 per telephone contact.
A total of $900 for completing the study.